BRPI0512099A - uso de ácido graxo poli-insaturado ("pufa") ou um sal ou derivado do mesmo farmacologicamente aceitável, método de tratamento tópico de condições, forma de dosagem oral, e, produto farmacêutico - Google Patents
uso de ácido graxo poli-insaturado ("pufa") ou um sal ou derivado do mesmo farmacologicamente aceitável, método de tratamento tópico de condições, forma de dosagem oral, e, produto farmacêuticoInfo
- Publication number
- BRPI0512099A BRPI0512099A BRPI0512099-3A BRPI0512099A BRPI0512099A BR PI0512099 A BRPI0512099 A BR PI0512099A BR PI0512099 A BRPI0512099 A BR PI0512099A BR PI0512099 A BRPI0512099 A BR PI0512099A
- Authority
- BR
- Brazil
- Prior art keywords
- derivative
- pharmaceutically acceptable
- fatty acid
- polyunsaturated fatty
- pufa
- Prior art date
Links
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000006186 oral dosage form Substances 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 201000002313 intestinal cancer Diseases 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
USO DE áCIDO GRAXO POLI-INSATURADO ("PUFA") OU UM SAL OU DERIVADO DO MESMO FARMACOLOGICAMENTE ACEITáVEL, MéTODO DE TRATAMENTO TóPICO DE CONDIçõES, FORMA DE DOSAGEM ORAL, E, PRODUTO FARMACêUTICO ácido graxo poli-insaturado ("PUFA") ou um sal ou derivado do mesmo farmacologicamente aceitável (tal como EPA e/ou DHA) é usado em combinação com pelo menos um de um agente imunossupressor ou um agente antineoplásico, dito agente (s) tendo pelo menos um resíduo de aminoácido, ou um sal farmacologicamente aceitável ou derivado do mesmo (tais como metotrexato ou ciclosporina) no tratamento de condições envolvendo resposta imune agudamente ou cronicamente inadequada. Condições específicas que podem ser tratadas incluem doença inflamatória crónica (por exemplo, doença de Crohn e colite ulcerativa) e doença provocada por tumor (por exemplo, câncer do intestino e câncer de próstata). Uma vantagem das modalidades preferidas da invenção é que a biodisponibilidade dos agentes imunossupressores ou antineoplásico é aumentada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413729.5A GB0413729D0 (en) | 2004-06-18 | 2004-06-18 | A pharmaceutical composition and its use |
| PCT/EP2005/006412 WO2005123060A1 (en) | 2004-06-18 | 2005-06-15 | A pharmaceutical composition and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512099A true BRPI0512099A (pt) | 2008-02-06 |
Family
ID=32750206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512099-3A BRPI0512099A (pt) | 2004-06-18 | 2005-06-15 | uso de ácido graxo poli-insaturado ("pufa") ou um sal ou derivado do mesmo farmacologicamente aceitável, método de tratamento tópico de condições, forma de dosagem oral, e, produto farmacêutico |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090018125A1 (pt) |
| EP (1) | EP1758573A1 (pt) |
| JP (1) | JP2008502630A (pt) |
| CN (1) | CN101027049A (pt) |
| AR (1) | AR049358A1 (pt) |
| AU (1) | AU2005253719A1 (pt) |
| BR (1) | BRPI0512099A (pt) |
| CA (1) | CA2569697A1 (pt) |
| GB (1) | GB0413729D0 (pt) |
| IL (1) | IL179795A0 (pt) |
| MX (1) | MXPA06014294A (pt) |
| NO (1) | NO20070338L (pt) |
| WO (1) | WO2005123060A1 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| WO2010119319A1 (en) | 2009-03-09 | 2010-10-21 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| HUE051916T2 (hu) | 2009-04-29 | 2021-04-28 | Amarin Pharmaceuticals Ie Ltd | Stabil gyógyászati készítmény és annak alkalmazási módszerei |
| SG177254A1 (en) | 2009-06-15 | 2012-02-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| KR102354949B1 (ko) * | 2009-10-23 | 2022-01-24 | 바스프 에이에스 | 지방산 오일 혼합물의 코팅된 캡슐 및 정제 |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| WO2012141575A1 (en) * | 2011-04-14 | 2012-10-18 | N.V.Nutricia | Combination of epa, dpa and/or dha with a chemotherapeutic agent |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| KR102153143B1 (ko) | 2012-01-06 | 2020-09-08 | 옴테라 파마슈티칼스, 인크. | 유리 산 형태의 오메가-3 다중불포화 지방산의 ｄｐａ-농축 조성물 |
| KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-３ 지방산의 조성물 |
| AU2013282394B2 (en) | 2012-06-29 | 2018-04-26 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US11351127B2 (en) | 2016-09-21 | 2022-06-07 | Avexxin As | Pharmaceutical composition |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| WO2020161088A1 (en) * | 2019-02-04 | 2020-08-13 | Dsm Ip Assets B.V. | Therapeutic combinations and compositions for the treatment of inflammatory bowel disease |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8729153D0 (en) * | 1987-12-14 | 1988-01-27 | Efamol Ltd | Fatty acid compositions |
| CH679119A5 (pt) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
| IE75744B1 (en) * | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
| GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| AU5928599A (en) * | 1999-09-09 | 2001-04-10 | Efa Sciences Llc. | Methods for treating cell proliferative disorders including cancer |
| US20040052837A1 (en) * | 2002-06-27 | 2004-03-18 | William Stillwell | Lipid conjugated anti-cancer drugs and methods of use thereof |
-
2004
- 2004-06-18 GB GBGB0413729.5A patent/GB0413729D0/en not_active Ceased
-
2005
- 2005-06-15 CN CNA2005800194523A patent/CN101027049A/zh active Pending
- 2005-06-15 JP JP2007515865A patent/JP2008502630A/ja active Pending
- 2005-06-15 US US11/629,093 patent/US20090018125A1/en not_active Abandoned
- 2005-06-15 EP EP05750805A patent/EP1758573A1/en not_active Withdrawn
- 2005-06-15 AU AU2005253719A patent/AU2005253719A1/en not_active Abandoned
- 2005-06-15 MX MXPA06014294A patent/MXPA06014294A/es not_active Application Discontinuation
- 2005-06-15 BR BRPI0512099-3A patent/BRPI0512099A/pt not_active Application Discontinuation
- 2005-06-15 WO PCT/EP2005/006412 patent/WO2005123060A1/en active Application Filing
- 2005-06-15 CA CA002569697A patent/CA2569697A1/en not_active Abandoned
- 2005-06-17 AR ARP050102495A patent/AR049358A1/es unknown
-
2006
- 2006-12-03 IL IL179795A patent/IL179795A0/en unknown
-
2007
- 2007-01-18 NO NO20070338A patent/NO20070338L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB0413729D0 (en) | 2004-07-21 |
| WO2005123060A1 (en) | 2005-12-29 |
| CN101027049A (zh) | 2007-08-29 |
| CA2569697A1 (en) | 2005-12-29 |
| EP1758573A1 (en) | 2007-03-07 |
| AU2005253719A1 (en) | 2005-12-29 |
| MXPA06014294A (es) | 2007-05-04 |
| IL179795A0 (en) | 2007-05-15 |
| AR049358A1 (es) | 2006-07-19 |
| NO20070338L (no) | 2007-03-09 |
| JP2008502630A (ja) | 2008-01-31 |
| US20090018125A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512099A (pt) | uso de ácido graxo poli-insaturado ("pufa") ou um sal ou derivado do mesmo farmacologicamente aceitável, método de tratamento tópico de condições, forma de dosagem oral, e, produto farmacêutico | |
| BRPI0511176A (pt) | uso de ácido graxo poliinsaturado ou sal farmacologicamente aceitável ou derivado do mesmo, método de tratamento tópico de condições envolvendo resposta imune agudamente ou cronicamente inadequada, forma de dosagem oral, e, produto farmacêutico | |
| Belluzzi et al. | Polyunsaturated fatty acids and inflammatory bowel disease | |
| EA200400242A1 (ru) | Фармацевтические композиции, содержащие бета-лапахон или его производные или аналоги, и способы их применения | |
| UY26779A1 (es) | Prodrogas 3` de 2' -desoxi-b-l-nucleósidos | |
| ES2074698T3 (es) | Composicion oral para el tratamiento de enfermedades intestinales inflamatorias. | |
| AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
| GEP20053511B (en) | ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase | |
| PA8580201A1 (es) | Terapia de combinacion para enfermedades hiperproliferativas | |
| MA26709A1 (fr) | Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| HUP0303817A2 (hu) | Közepes lánchosszúságú zsírsavak, gliceridek és analógok, mint neutrofil túlélési és aktivitási faktorok és ezeket tartalmazó gyógyszerkészítmények | |
| CY1110391T1 (el) | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους | |
| IL158903A0 (en) | Use of sulodexide for the treatment of inflammatory bowel disease | |
| CA2534202A1 (en) | Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination | |
| MA56390A (fr) | Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| NO20023962L (no) | Bruk av IL-18-inhibitorer | |
| HRP20161197T1 (hr) | 24-norudca za liječenje autoimunog hepatitisa | |
| SV2002000235A (es) | Composiciones farmaceuticas que comprenden valdecoxib | |
| BRPI0414305A (pt) | sistema de liberação de drogas por via oral | |
| MA30665B1 (fr) | Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee. | |
| EA200700353A1 (ru) | Средство антимикробного действия | |
| AR029451A1 (es) | Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia | |
| TNSN04101A1 (fr) | ASSOCIATIONS PHARMACEUTIQUES D'UN AGONISTE DE RECEPTEUR D'ADENOSINE A2a ET D'UN AGONISTE DE RECEPTEUR ADRENERGIQUE B2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |